KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 30,500 shares, a decline of 18.7% from the October 31st total of 37,500 shares. Based on an average daily trading volume, of 21,400 shares, the short-interest ratio is presently 1.4 days. Approximately 0.8% of the company’s shares are short sold.

Hedge Funds Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP bought a new position in KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises about 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest position. SR One Capital Management LP owned 15.76% of KALA BIO as of its most recent SEC filing. 24.61% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of KALA BIO in a research note on Friday, November 15th. Oppenheimer restated an “outperform” rating and set a $15.00 target price on shares of KALA BIO in a report on Monday, August 19th.

KALA BIO Stock Down 2.0 %

Shares of NASDAQ:KALA traded down $0.14 during midday trading on Monday, hitting $6.72. 2,710 shares of the company’s stock traded hands, compared to its average volume of 81,772. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. The company has a market cap of $30.98 million, a PE ratio of -0.54 and a beta of -2.13. The firm’s fifty day moving average price is $6.17 and its two-hundred day moving average price is $6.26. KALA BIO has a twelve month low of $4.21 and a twelve month high of $10.97.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. On average, equities research analysts anticipate that KALA BIO will post -10.84 EPS for the current fiscal year.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.